ARTICLE | Clinical News
PF-06671008: Phase I started
May 16, 2016 7:00 AM UTC
MacroGenics said Pfizer began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial of PF-06671008 in about 110 patients with tumors that potentially express CDH3. The start triggered a $...